Top

Published in:

01-10-2007 | Original Article

Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane^®) on three treatment schedules in patients with solid tumors

Authors: Thomas E. Stinchcombe, Mark A. Socinski, Christine M. Walko, Bert H. O’Neil, Frances A. Collichio, Anastasia Ivanova, Hua Mu, Michael J. Hawkins, Richard M. Goldberg, Celeste Lindley, E. Claire Dees

Published in: Cancer Chemotherapy and Pharmacology | Issue 5/2007

Abstract

Purpose

Albumin-bound paclitaxel, ABI-007 (Abraxane^®), has a different toxicity profile than solvent-based paclitaxel, including a lower rate of severe neutropenia. The combination of ABI-007 and carboplatin may have significant activity in a variety of tumor types including non-small and small cell lung cancer, ovarian cancer, and breast cancer. The purpose of this study was to determine the maximum tolerated dose (MTD) of ABI-007, on three different schedules in combination with carboplatin.

Methods

Forty-one patients with solid tumors were enrolled, and received ABI-007 in combination with carboplatin AUC of 6 on day 1. Group A received ABI-007 at doses ranging from 220 to 340 mg/m² on day 1 every 21 days; group B received ABI-007 at 100 or 125 mg/m² on days 1, 8, and 15 every 28 days; and group C received ABI-007 125 or 150 mg/m² on days 1 and 8 every 21 days. Dose-limiting toxicities were assessed after the first cycle. Doses were escalated in cohorts of three to six patients. Fifteen patients participated in a pharmacokinetic study investigating the effects of the sequence of infusion. ABI-007 was infused first followed by carboplatin in cycle 1, and vice versa in cycle 2.

Results

The MTD of ABI-007 in combination with carboplatin was 300, 100, and 125 mg/m² in groups A, B, and C, respectively. Myelosuppression was the primary dose limiting toxicity. No unexpected or new toxicities were reported. Sequence of infusion did not affect either the pharmacokinetics of ABI-007 or the degree of neutropenia. Responses were seen in melanoma, lung, bladder, esophageal, pancreatic, breast cancer, and cancer of unknown primary.

Conclusions

The recommended dose for phase II studies of ABI-007 in combination with carboplatin (AUC of 6) is 300, 100, 125 mg/m² for the schedules A, B, and C, respectively. The combination of ABI-007 and carboplatin is well tolerated and active in this heavily pretreated patient population.

Socinski MA (1999) Single-agent paclitaxel in the treatment of advanced non-small cell lung cancer. Oncologist 4(5):408–416PubMed

Crown J, O’Leary M (2000) The taxanes: an update. Lancet 355(9210):1176–1178PubMedCrossRef

Gelderblom H, Verweij J, Nooter K, Sparreboom A (2001) Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 37(13):1590–1598PubMedCrossRef

Authier N, Gillet JP, Fialip J, Eschalier A, Coudore F (2001) Assessment of neurotoxicity following repeated cremophor/ethanol injections in rats. Neurotox Res 3(3):301–306PubMedCrossRef

Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P et al (2005) Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23(31):7794–7803PubMedCrossRef

Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346(2):92–98PubMedCrossRef

Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA et al (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21(17):3194–3200PubMedCrossRef

Burris H 3rd, Yardley D, Jones S, Houston G, Broome C, Thompson D et al (2004) Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer. J Clin Oncol 22(9):1621–1629PubMedCrossRef

Rowinsky EK, Gilbert MR, McGuire WP, Noe DA, Grochow LB, Forastiere AA et al (1991) Sequences of taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol 9(9):1692–1703PubMed

10.

Huizing MT, Giaccone G, van Warmerdam LJ, Rosing H, Bakker PJ, Vermorken JB et al (1997) Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer The European cancer centre. J Clin Oncol 15(1):317–329PubMed

11.

Markman M, Elson P, Kulp B, Peterson G, Zanotti K, Webster K et al (2003) Carboplatin plus paclitaxel combination chemotherapy: impact of sequence of drug administration on treatment-induced neutropenia. Gynecol Oncol 91(1):118–122PubMedCrossRef

12.

Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, National cancer institute of the United States, National cancer institute of Canada. J Natl Cancer Inst 92(3):205–216PubMedCrossRef

13.

Calvert AH, Newell DR, Gumbrell LA, O’Reilly S, Burnell M, Boxall FE et al (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7(11):1748–1756PubMed

14.

Ibrahim NK, Samuels B, Page R, Doval D, Patel KM, Rao SC et al (2005) Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol 23(25):6019–6026PubMedCrossRef

15.

Ibrahim NK, Desai N, Legha S, Soon-Shiong P, Theriault RL, Rivera E et al (2002) Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 8(5):1038–1044PubMed

16.

Kosmidis P, Mylonakis N, Skarlos D, Samantas E, Dimopoulos M, Papadimitriou C et al (2000) Paclitaxel (175 mg/m2) plus carboplatin (6 AUC) versus paclitaxel (225 mg/m2) plus carboplatin (6 AUC) in advanced non-small-cell lung cancer (NSCLC): a multicenter randomized trial. Hellenic cooperative oncology group (HeCOG). Ann Oncol 11(7):799–805PubMedCrossRef

17.

Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355(24):2542–2550PubMedCrossRef

18.

Nyman DW, Campbell KJ, Hersh E, Long K, Richardson K, Trieu V et al (2005) Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J Clin Oncol 23(31):7785–7793PubMedCrossRef

19.

Allerton JP, Hagenstad CT, Webb RT, Smith GB, Birch R, Goggins TF et al (2006) A phase II evaluation of the combination of paclitaxel protein-bound and carboplatin in the first line treatment of advanced non-small cell lung cancer (NSCLC). J Clin Oncol (ASCO Annual Meetings Proceedings) 24(18S):7127 (abstract)

20.

Hawkins MJ, Georgy M, Makhson A, Cheporov S, Sergey O, Yablonsky P et al (2006) Dose escalation study of nab-paclitaxel followed by carboplatin a first line therapy in advanced non-small cell lung cancer (NSCLC). J Clin Oncol (ASCO Annual Meetings Proceedings) 24(18S):7132 (abstract)

21.

Socinski MA, Schell MJ, Peterman A, Bakri K, Yates S, Gitten R et al (2002) Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol 20(5):1335–1343PubMedCrossRef

Title: Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane®) on three treatment schedules in patients with solid tumors
Authors: Thomas E. Stinchcombe
Mark A. Socinski
Christine M. Walko
Bert H. O’Neil
Frances A. Collichio
Anastasia Ivanova
Hua Mu
Michael J. Hawkins
Richard M. Goldberg
Celeste Lindley
E. Claire Dees
Publication date: 01-10-2007
Publisher: Springer-Verlag
Published in: Cancer Chemotherapy and Pharmacology / Issue 5/2007
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-007-0423-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2007

Tetrandrine achieved plasma concentrations capable of reversing MDR in vitro and had no apparent effect on doxorubicin pharmacokinetics in mice

Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer

Gemcitabine plus docetaxel as first-line chemotherapy in patients with advanced non-small cell lung cancer: a lung cancer Galician group phase II study

Local delivery of temozolomide by biodegradable polymers is superior to oral administration in a rodent glioma model

Synergistic interaction between tetrandrine and chemotherapeutic agents and influence of tetrandrine on chemotherapeutic agent-associated genes in human gastric cancer cell lines

Role of NADPH cytochrome P450 reductase in activation of RH1

Keynote webinar | Spotlight on antibody–drug conjugates in cancer